Melioidosis, a tropical disease caused by the environmental bacterium Burkholderia pseudomallei, often manifests as severe sepsis, with a mortality rate of 35% among affected patients in Northeast Thailand. Early diagnosis is crucial for effective treatment, yet traditional bacterial culture methods are time-consuming and have low sensitivity. The project has developed a rapid immunochromatography test (Hcp1-ICT) based on hemolysin-coregulated protein (Hcp1), which has shown a sensitivity of 76% and specificity of 92% in preliminary evaluations at Mukdahan Hospital. Combining Hcp1-ICT with type-3 secretion system 1 quantitative PCR (TTS1-qPCR) significantly enhances diagnostic performance, achieving a sensitivity of 98%. The project aims to investigate whether the implementation of these combined diagnostic tools can reduce mortality from melioidosis and whether plasma IL-1R2 can serve as an effective biomarker for predicting sepsis-related mortality. Through a multi-center prospective study, the project will assess the impact of these innovations on patient management and treatment decisions, ultimately addressing the global burden of melioidosis and sepsis, which represents a significant public health threat.